title: Evidence that kinin B2 receptor expression is upregulated by endothelial overexpression of B1 receptors.
abstract: Bradykinin (BK) and des-Arg(9)-bradykinin (DBK) of kallikrein-kinin system exert its effects mediated by the B2 (B2R) and B1 (B1R) receptors, respectively. It was already shown that the deletion of kinin B1R or of B2R induces upregulation of the remaining receptor subtype. However studies on overexpression of B1R or B2R in transgenic animals have supported the importance of the overexpressed receptor but the expression of another receptor subtype has not been determined. Previous study described a marked vasodilatation and increased susceptibility to endotoxic shock which was associated with increased mortality in response to DBK in thoracic aorta from transgenic rat overexpressing the kinin B1R (TGR(Tie2B1)) exclusively in the endothelium. In another study, mice overexpressing B1R in multiple tissues were shown to present high susceptibility to inflammation and to lipopolysaccharide-induced endotoxic shock. Therefore the role of B2R was investigated in the thoracic aorta isolated from TGR(Tie2B1) rats overexpressing the B1R exclusively in the vascular endothelium. Our findings provided evidence for highly increased expression level of the B2R in the transgenic rats. It was reported that under endotoxic shock, these rats exhibited exaggerated hypotension, bradycardia and mortality. It can be suggested that the high mortality during the pathogenesis of endotoxic shock provoked in the transgenic TGR(Tie2B1) rats could be due to the enhanced expression of B2R associated with the overexpression of the B1R.
authors.affiliation: Department of Biophysics, Federal University of São Paulo, São Paulo 04023-062, Brazil.
authors.forename: Eliete S
authors.initials: ES
authors.lastname: Rodrigues
authors.forename: Rafael F
authors.initials: RF
authors.lastname: Silva
authors.forename: Renan P
authors.initials: RP
authors.lastname: Martin
authors.forename: Suzana M
authors.initials: SM
authors.lastname: Oliveira
authors.forename: Clovis R
authors.initials: CR
authors.lastname: Nakaie
authors.forename: Regiane A
authors.initials: RA
authors.lastname: Sabatini
authors.forename: Vanessa F
authors.initials: VF
authors.lastname: Merino
authors.forename: João B
authors.initials: JB
authors.lastname: Pesquero
authors.forename: Michael
authors.initials: M
authors.lastname: Bader
authors.forename: Suma I
authors.initials: SI
authors.lastname: Shimuta
mesh_terms: D000110:Acetylcholinesterase / Q000032:analysis / Q000378:metabolism; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000187:drug effects; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology; D065169:Bradykinin B1 Receptor Antagonists; D004730:Endothelium, Vascular / Q000502:physiology*; D005786:Gene Expression Regulation; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D055647:Rats, Transgenic; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D043783:Receptor, Bradykinin B1 / Q000235:genetics / Q000378:metabolism*; D043782:Receptor, Bradykinin B2 / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation; D014664:Vasodilation / Q000187:drug effects
chemical_list: D065169:Bradykinin B1 Receptor Antagonists; C120984:R 715; D044140:Receptor, Angiotensin, Type 1; D043783:Receptor, Bradykinin B1; D043782:Receptor, Bradykinin B2; D000804:Angiotensin II; C065679:icatibant; D000110:Acetylcholinesterase; D001920:Bradykinin; D019331:NG-Nitroarginine Methyl Ester; D007213:Indomethacin